33 Recruiting Studies Using Tislelizumab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Tislelizumab
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
📍 Mayo Clinic — Scottsdale, Arizona
Gastric Cancer
View Study & Checklist ➔First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
📍 Moffitt Cancer Center — Tampa, Florida
Prostate Cancer
View Study & Checklist ➔A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
Renal Cell Carcinoma
View Study & Checklist ➔Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
📍 Los Angeles General Medical Center — Los Angeles, California
Advanced Malignant Skin Neoplasm
View Study & Checklist ➔A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
📍 Johns Hopkins SKCCC — Baltimore, Maryland
Pancreatic Cancer
View Study & Checklist ➔A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
📍 Hospital de Gastroenterología Dr Bonorino Udaondo — Buenos Aires,
Gastric Neoplasms
View Study & Checklist ➔A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
📍 Ambulatory Care Center — New York, New York
Pancreatic Cancer
View Study & Checklist ➔A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
📍 Alaska Oncology and Hematology, Llc — Anchorage, Alaska
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
View Study & Checklist ➔A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
📍 Valkyrie Clinical Trials — Los Angeles, California
Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
📍 Valkyrie Clinical Trials — Los Angeles, California
Non-small Cell Lung Cancer
View Study & Checklist ➔A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
📍 Banner Md Anderson Cancer Center — Gilbert, Arizona
B-cell Malignancies
View Study & Checklist ➔Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
📍 Emory University School of Medicine-Winship Cancer Institute — Atlanta, Georgia
KRAS G12C Mutant Solid Tumors
View Study & Checklist ➔A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
📍 MD Anderson Cancer Center — Houston, Texas
Minimal Residual Disease
View Study & Checklist ➔Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
📍 University of Southern California- Norris Cancer Center — Los Angeles, California
Solid Tumor, Adult
View Study & Checklist ➔ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
📍 Verspeeten Family Cancer Centre — London, Ontario
Advanced Pancreatic Ductal Adenocarcinoma
View Study & Checklist ➔A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
📍 Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Pancreatic Cancer
View Study & Checklist ➔A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
📍 University Health Network (UHN) — Toronto, Ontario
Large B-cell Lymphoma
View Study & Checklist ➔A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
📍 City of Hope National Medical Center — Duarte, California
Advanced Solid Tumor
View Study & Checklist ➔A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
📍 Helios Clinical Research — Cerritos, California
Advanced Unresectable Gastric Adenocarcinoma
View Study & Checklist ➔AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
📍 University of California, Los Angeles — Los Angeles, California
Gastroesophageal Adenocarcinoma
View Study & Checklist ➔A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
📍 Washington University School of Medicine — St Louis, Missouri
Advanced Solid Tumor
View Study & Checklist ➔Tislelizumab in People With Colorectal Cancer
📍 Memorial Sloan Kettering Cancer Center — New York, New York
Colorectal Cancer
View Study & Checklist ➔A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
📍 City of Hope Phoenix Cancer Center — Goodyear, Arizona
Metastatic Hepatocellular Carcinoma
View Study & Checklist ➔Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
📍 Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Carcinoma, Hepatocellular
View Study & Checklist ➔Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
📍 Usc Norris Comprehensive Cancer Center (Nccc) — Los Angeles, California
Advanced Solid Tumor
View Study & Checklist ➔Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Advanced Solid Tumor
View Study & Checklist ➔Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
📍 Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
Pancreatic Adenocarcinoma Metastatic
View Study & Checklist ➔Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
📍 Highlands Oncology Group — Springdale, Arkansas
NSCLC Stage IV
View Study & Checklist ➔BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
📍 Yale New Haven Hospital — New Haven, Connecticut
Advanced Solid Tumor
View Study & Checklist ➔A Study of BG-C477 in Participants With Advanced Solid Tumors
📍 City of Hope Phoenix Cancer Center — Goodyear, Arizona
Advanced Solid Tumors
View Study & Checklist ➔Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
📍 The University of Chicago — Chicago, Illinois
Head and Neck Cancer
View Study & Checklist ➔Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
📍 Carolina BioOncology Institute — Huntersville, North Carolina
Non Small Cell Lung Cancer
View Study & Checklist ➔Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
📍 Novartis Investigative Site — Sint-Niklaas, Oost Vlaanderen
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer
View Study & Checklist ➔